In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.
The in vitro activities of 12 macrolide compounds against 28 Mycobacterium avium complex strains isolated from patients with acquired immunodeficiency syndrome were determined by the conventional proportion method and by the BACTEC method. Clarithromycin (A-56268; TE-031), a new macrolide compound, was the most active agent tested, inhibiting 90% of strains at an MIC of 4 micrograms/ml by the BACTEC method. Roxithromycin (RU 28965) and erythromycylamine inhibited 90% of strains at 16 micrograms/ml. The organisms showed high levels of resistance to most other macrolide compounds.
Naik
S
S
Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany 12201-0509.
Ruck
R
R
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004917:Erythromycin / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests; D015269:Mycobacterium avium Complex / Q000187:drug effects*; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000382:microbiology
D000900:Anti-Bacterial Agents; D004917:Erythromycin